Noninvasive monitoring of colonic carcinogenesis: feasibility of [18F]FDG-PET in the azoxymethane model
Introduction
Colorectal adenocarcinoma (CRC) is highly prevalent and a common cause of cancer-related deaths in the Western world [1], [2]. The high disease burden has led to experimental carcinogenesis models that allow the study of the biology of cancer and the evaluation of pharmacological interventions. Azoxymethane is a potent carcinogen that induces colorectal cancers in rats and mice. The spectrum of AOM-induced epithelial lesions resembles those of the various types of neoplastic lesions in human CRC. In addition, AOM-induced CRC appears to follow the concept in which tumor initiation is followed by tumor promotion and progression in a sequential manner. Specifically, AOM induces the onset of aberrant crypt foci, as the precursor lesion, followed by the onset of adenocarcinoma most often of the distal colon, and, finally, metastasis to mesenteric lymph nodes and liver. The molecular pathogenesis is characterized by K-ras and/or beta catenin mutations. Unique to the AOM rat model is the co-occurrence of both adenomas and adenocarcinomas, and it has been estimated that 70% of colon tumors are adenocarcinomas, while the remainder are adenomas. Histologically, adenomas of the colon are noninvasive with low- to high-grade dysplasia [3].
[18F]FDG-PET is a molecular imaging technique that is based on the elevated uptake and retention of radiolabeled glucose in target tissues. The FDG uptake detected by scans allows for estimation of the cellular energy metabolism and can be used to detect stage and assess treatment of many processes, most notably malignancies [4]. FDG-PET has also been used for research purposes because it offers metabolic/functional images noninvasively, quantitatively and repeatedly, not only in humans but also in small animals. At present, it is unknown at which stage FDG accumulation occurs during the adenoma–carcinoma sequence of CRC. We reasoned that the CRC of the AOM rat model is associated with higher metabolic activity and hence increased FDG uptake. Furthermore, this model allows us to evaluate whether FDG already accumulates in adenomas. Ultimately, our goal is to develop an experimental model of metabolic imaging that visualizes the carcinogenesis of CRCs. An ideal model would allow noninvasive monitoring of the efficacy of cancer intervention/prevention strategies. To address this issue, we studied the FDG uptake in AOM-induced rat CRC and correlated this with histopathological findings.
Section snippets
Experimental model
We used the AOM rat model [5] because of the apparent similarity of the induced tumors to those occurring in humans [6]. These animals develop colonic adenomas and colon carcinomas within 5 months after AOM treatment [7]. We obtained 70 male weanling Fischer 344 rats from Charles River (Sulzfeld, Germany). Animals were kept on softwood bedding in macrolon cages, two or three per cage, under standard laboratory conditions. Rats were fed the Institute's stock diet for rats. Azoxymethane (NCI
Macroscopic examination
Macroscopic examination of small and large bowels revealed 21 tumors in 19 rats, which started to appear 22 weeks after the first AOM injection. Macroscopic inspection of the intestines demonstrated small bowel tumors in 7 animals, all located in the proximal part of the small bowel directly distal from the stomach. Fourteen tumors were located in the large bowel (n=4 distal part, n=9 mid large bowel, n=1 cecum). Two animals had more than one gastrointestinal tumor. One rat had tumors in both
Discussion
In the present study, we investigated whether [18F]FDG accumulates preferentially in (pre)malignant lesions induced by AOM in an experimental rat model. Here we show that three subcutaneous injections of AOM induced both adenomas and adenocarcinomas in the colon as well as small intestine carcinomas in F344 rats. The first adenomas appeared 22 weeks after the start of AOM injections. There was no correlation between time after AOM treatment and the appearance of gastrointestinal adenomas and
Acknowledgments
Joost P.H. Drenth is supported by a VIDI fellowship from the Netherlands Organization for Scientific Research (NWO). This work was supported in part by a Gastrostart grant from the Dutch Society of Gastroenterology. Mrs. Cathelijne Frielink is acknowledged for expert help in preparing the histological samples.
References (10)
- et al.
Cancer statistics, 2001
CA Cancer J Clin
(2001) - et al.
Incidence of colorectal carcinoma in the US — An update of trends by gender, race, age, subsite, and stage, 1975–1994
Cancer
(1999) Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention
Environ Mol Mutagen
(2004)Oncological applications of FDG PET imaging: brain tumors, colorectal cancer lymphoma and melanoma
J Nucl Med
(1999)Dose response to a single injection of azoxymethane in rats. Induction of tumors in the gastrointestinal tract, auditory sebaceous glands, kidney, liver and preputial gland
Vet Pathol
(1975)
Cited by (12)
Characterization of the Pro-Inflammatory Cytokine IL-1β on Butyrate Oxidation in Colorectal Cancer Cells
2017, Journal of Cellular BiochemistryTraditional serrated adenomas and serrated carcinomas in carcinogen-treated rats
2017, Journal of Clinical PathologyThree pathways of colonic carcinogenesis in rats
2017, Anticancer ResearchCellular Metabolism and Dose Reveal Carnitine-Dependent and -Independent Mechanisms of Butyrate Oxidation in Colorectal Cancer Cells
2016, Journal of Cellular Physiology